Envoy Medical Completes Enrollment of Pivotal Clinical Trial Evaluating First-Of-Its-Kind Fully Implanted Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - March 11, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced completed enrollment of its pivotal clinical trial for the investigational fully implanted Acclaim® cochlear implant. With the successful implantation of the 56th and final patient, Envoy Medical is the first cochlear implant company to achieve full enro
Biotechnologies, Soins de santé et hôpitaux
2026-03-11 8:00 AM EDT | Envoy Medical, Inc.
Restart Life Highlights Certified Manufacturing Platform to Drive Margin Expansion and Distribution Growth
Vancouver, British Columbia--(Newsfile Corp. - March 11, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide investors with an update on the strategic value of the Holy Crap™ manufacturing facility and its role in supporting scalable growth, margin expansion, and broader market distribution across the Company's functional wellness portfolio. The Holy Crap™ production facility operates under mul
Technologies, Biotechnologies, Santé
2026-03-11 8:00 AM EDT | Restart Life Sciences Corp.
TempraMed's Independently Validated Payer ROI Model for Reimbursement Further Reinforced by a Scientific Publication Highlighting Clinical and Economic Rationale for VIVI Cap
Vancouver, British Columbia--(Newsfile Corp. - March 11, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the publication of a clinical case report evaluating the use of VIVI Cap™ for passive thermal protection of insulin during summer travel. The paper, titled "Passive Thermal Protection
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-03-11 7:00 AM EDT | TempraMed Technologies Ltd.
Theralase(R) Closes $1.1 M Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - March 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-03-10 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT
King of Prussia, Pennsylvania--(Newsfile Corp. - March 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12th
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-03-10 7:00 AM EDT | Phio Pharmaceuticals Corp.
Hemostemix Leadership Attending Abundance360 Summit
Calgary, Alberta--(Newsfile Corp. - March 9, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced that Thomas Smeenk CEO and Peter Lacey, Chairman are attending the 2026 Abundance360 Summit in Los Angeles this week. Founded by futurist and entrepreneur Peter H. Diamandis, the annual Abundance360 Summit convenes leading entrepreneurs, and investors, working at the frontiers of biotechnology, artificial intelligence, longevity science, and other exponential techn
Biotechnologies, Pharmaceutique, Santé
2026-03-09 11:23 AM EDT | Hemostemix Inc.
OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting
New York, New York--(Newsfile Corp. - March 9, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today provided an update regard
2026-03-09 7:40 AM EDT | OS Therapies
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small
Biotechnologies, Pharmaceutique
2026-03-09 7:30 AM EDT | InMed Pharmaceuticals
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to present its latest preclinical data demonstrating that X-Ray-activated Rutherrin® is effective in th
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-03-09 7:00 AM EDT | Theralase Technologies Inc.
Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement offering (the "Offering") of non-transferable secured convertib
2026-03-09 7:00 AM EDT | Telo Genomics Corp.
Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
Montreal, Quebec--(Newsfile Corp. - March 9, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the closing of a private placement (the "Private Placement") of 17,445,455 units (the "Units") at a price of $0.55 per Unit, for aggregate gross proceeds to Defence of $9,595,000.25. Each Unit is comprised
Biotechnologies, Pharmaceutique, Santé
2026-03-09 3:15 AM EDT | Defence Therapeutics Inc.
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline
Vancouver, British Columbia--(Newsfile Corp. - March 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1/CB2 receptors, today announced an update regarding BayMedica LLC ("BayMedica"), a wholly owned subsidiary of the Company, in light of ongoing uncertainty surrounding U.S. federal legislation. As previously annou
Biotechnologies, Pharmaceutique
2026-03-06 5:04 PM EST | InMed Pharmaceuticals
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeuti
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-03-05 4:05 PM EST | Phio Pharmaceuticals Corp.
BioHarvest Sciences Announces Board Transition and Appointment of Prof. Hezi Levy
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 5, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology, today announced that Mr. David Tsur will step down from its Board of Directors after more than four years of service. The Company further announced the appointment of Prof. Hezi Levy to its Board of Directors, effective immediately. Mr. Tsur has served on BioHarvest's Board since 2021 and
Biotechnologies, Pharmaceutique, Santé
2026-03-05 7:30 AM EST | BioHarvest Sciences Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-03-05 7:00 AM EST | Phio Pharmaceuticals Corp.
Octane Medical Group Signs Agreement to Acquire Lonza's Personalized Medicine Business
Kingston, Ontario--(Newsfile Corp. - March 4, 2026) - Octane Medical Group ("Octane") today announced that it has entered into a definitive agreement to acquire Lonza's Personalized Medicine business. For Octane, this is a strategically significant deal that comprises Lonza's controlling stake in the Cocoon® Platform - originally acquired from Octane in 2018 - alongside associated intellectual property (IP), workforce and existing customer contracts. Completion of the transact
Biotechnologies, Pharmaceutique
2026-03-04 6:00 PM EST | Octane Medical Group
Marvel Biosciences Sponsors Scientific Meeting on Purines
Calgary, Alberta--(Newsfile Corp. - March 4, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a biotechnology company developing novel therapies for neurological and neurodevelopmental disorders, today announced it is sponsoring the 3rd European Purine Meeting taking place in Bordeaux, France, from June 30 to July 3, 2026. The 3rd European Puri
2026-03-04 7:00 AM EST | Marvel Biosciences Corp.
Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval
Ontario and Boston, Massachusetts--(Newsfile Corp. - March 4, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSHO) ("Sernova" or the "Company"), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced financing transactions totaling $7.1 million, significantly strengthening the Company's balance sheet and financial position. The transactions include:
2026-03-04 7:00 AM EST | Sernova Biotherapeutics
Zenith Capital Corp. Appoints Bryan Ede to Board of Directors
Calgary, Alberta--(Newsfile Corp. - March 3, 2026) - Zenith Capital Corp. ("Zenith" or the "Company") today announces the appointment of Mr. Bryan R. Ede, J.D. as a member of the Company's Board of Directors following the retirement of Dr. Norman Wong, M.D. as a member of the Board. Mr. Ede worked over 27 years in Calgary as a commercial lawyer. He was a national firm Equity Partner for McMillan LLP and Miller Thomson LLP and has extensive law firm management experience as a Calga
2026-03-03 6:15 PM EST | Zenith Capital Corp.
Jeffrey W. Sherman, MD, Joins DIMERx Board to Advance Next-Generation, Non-Addictive Pain Therapies
San Francisco, California--(Newsfile Corp. - March 3, 2026) - DIMERx, Inc. ("DIMERx" or "the Company"), is a clinical-stage biopharmaceutical company dedicated to addressing the public-health crisis of drug abuse and dependence, with a portfolio of first-in-class, dimer-based pain therapeutics engineered to deliver effective analgesia without the addiction liabilities of conventional opioids. The Company announced the appointment of Jeffrey W. Sherman, MD, FACP, to its Board of Directors. Dr.
Biotechnologies, Pharmaceutique, Santé
2026-03-03 9:00 AM EST | DIMERx INC.